Log in

XBiotech Stock Forecast, Price & News

+0.53 (+2.88 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $18.95
50-Day Range
MA: $18.42
52-Week Range
Now: $18.95
Volume124,935 shs
Average Volume434,122 shs
Market Capitalization$549.34 million
P/E Ratio1.31
Dividend YieldN/A
XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection and influenza diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Read More
XBiotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:XBIT



Sales & Book Value

Annual SalesN/A
Book Value$18.20 per share


Net Income$668.63 million


Market Cap$549.34 million
Next Earnings Date11/10/2020 (Estimated)
+0.53 (+2.88 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

XBiotech (NASDAQ:XBIT) Frequently Asked Questions

How has XBiotech's stock been impacted by Coronavirus (COVID-19)?

XBiotech's stock was trading at $10.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XBIT shares have increased by 76.8% and is now trading at $18.95.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of XBiotech?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for XBiotech

When is XBiotech's next earnings date?

XBiotech is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for XBiotech

How were XBiotech's earnings last quarter?

XBiotech Inc (NASDAQ:XBIT) announced its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $15.50 million during the quarter.
View XBiotech's earnings history

What price target have analysts set for XBIT?

2 Wall Street analysts have issued 12 month price objectives for XBiotech's shares. Their forecasts range from $18.00 to $28.00. On average, they expect XBiotech's share price to reach $23.00 in the next year. This suggests a possible upside of 21.4% from the stock's current price.
View analysts' price targets for XBiotech

Are investors shorting XBiotech?

XBiotech saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 2,040,000 shares, an increase of 9.7% from the August 15th total of 1,860,000 shares. Based on an average daily trading volume, of 199,300 shares, the days-to-cover ratio is presently 10.2 days. Approximately 14.6% of the shares of the company are sold short.
View XBiotech's Short Interest

Who are some of XBiotech's key competitors?

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), Pfizer (PFE), Inovio Pharmaceuticals (INO), Intel (INTC), Square (SQ) and CVS Health (CVS).

Who are XBiotech's key executives?

XBiotech's management team includes the following people:
  • Mr. John Simard, Founder, Pres, CEO & Chairman (Age 57)
  • Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 41)
  • Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 52)
  • Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 63)
  • Dr. William Levis, Interim Medical Director and Member of Scientific Advisory Board

When did XBiotech IPO?

(XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

Who are XBiotech's major shareholders?

XBiotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Jane Street Group LLC (0.40%), Russell Investments Group Ltd. (0.39%), AQR Capital Management LLC (0.27%), Nuveen Asset Management LLC (0.23%), Bank of New York Mellon Corp (0.22%) and Alps Advisors Inc. (0.14%). Company insiders that own XBiotech stock include Fondation Rennes, Queena Han, Street Financial SA Bay, Sushma Shivaswamy and W Thorpe Mckenzie.
View institutional ownership trends for XBiotech

Which institutional investors are selling XBiotech stock?

XBIT stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Goldman Sachs Group Inc., Jane Street Group LLC, and Alps Advisors Inc.. Company insiders that have sold XBiotech company stock in the last year include Queena Han, Street Financial SA Bay, and Sushma Shivaswamy.
View insider buying and selling activity for XBiotech

Which institutional investors are buying XBiotech stock?

XBIT stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Swiss National Bank, WINTON GROUP Ltd, Bridgeway Capital Management Inc., Bank of New York Mellon Corp, Strs Ohio, Russell Investments Group Ltd., and Virtus ETF Advisers LLC. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes, and W Thorpe Mckenzie.
View insider buying and selling activity for XBiotech

How do I buy shares of XBiotech?

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $18.95.

How big of a company is XBiotech?

XBiotech has a market capitalization of $549.34 million. The biopharmaceutical company earns $668.63 million in net income (profit) each year or ($0.68) on an earnings per share basis. XBiotech employs 56 workers across the globe.

What is XBiotech's official website?

The official website for XBiotech is www.xbiotech.com.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]

This page was last updated on 9/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.